FDA CONCURS: No confirmation of new GLP-1, DPP-4 pancreatic concerns
This article was originally published in Scrip
Executive Summary
After alerting prescribers and patients in March about the possibility GLP-1-based diabetes therapies, also known as incretin mimetics, increase the risk of pancreatitis and pre-cancerous cellular changes in patients with type 2 diabetes, the FDA joined European regulators in concluding the currently available data do not confirm those concerns.